Neurocrine Biosciences Q3 revenue jumps 41% on strong INGREZZA, CRENESSITY, VYKAT XR demand
Overview
US biopharma firm's Q3 revenue grew 41% yr/yr, driven by strong product sales
Adjusted EPS and adjusted net income for Q3 beat analyst expectations
Company raised full-year 2026 INGREZZA sales guidance on continued strong demand
Outlook
Company raises 2026 INGREZZA net product sales guidance to $2.9-$2.925 bln
Company maintains 2026 R&D expense guidance at $1.275-$1.325 bln (GAAP) and $1.14-$1.19 bln (Non-GAAP)
Company lowers 2026 SG&A expense guidance to $1.54-$1.56 bln (GAAP) and $1.29-$1.31 bln (Non-GAAP)
Result Drivers
INGREZZA DEMAND - Q3 sales rose 17% yr/yr, driven by double-digit volume growth, record prescriptions and high persistency, per co
CRENESSITY GROWTH - Q3 sales more than doubled yr/yr, supported by steady new patient demand, high persistency and ~80% reimbursement, per co
VYKAT XR CONTRIBUTION - Q3 sales reached $107 mln, driven by steady and consistent patient demand and persistency, per co
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Adjusted EPS | Beat | $3.29 | $1.91 (21 Analysts) |
Q3 EPS | $1.96 | ||
Q3 Adjusted Net Income | Beat | $347 mln | $203.82 mln (18 Analysts) |
Q3 Net Income | $207 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 27 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Neurocrine Biosciences, Inc. is $210.00, about 43.7% above its October 30 closing price of $146.10
The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 19 three months ago
Reuters Recommended Reads
Nov 2 - Vertex Pharmaceuticals' Q3 revenue slightly beats estimates, outlook raised
Nov 2 - Travere Q3 product sales nearly double on FILSPARI growth
Nov 2 - Syndax Pharmaceuticals Q3 revenue rises 82% on cancer drug sales
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)